
Chimeric Therapeutics Ltd
ASX:CHM

Intrinsic Value
The intrinsic value of one
CHM
stock under the Base Case scenario is
0.01
AUD.
Compared to the current market price of 0.005 AUD,
Chimeric Therapeutics Ltd
is
Undervalued by 51%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Chimeric Therapeutics Ltd
Fundamental Analysis


Revenue & Expenses Breakdown
Chimeric Therapeutics Ltd
Balance Sheet Decomposition
Chimeric Therapeutics Ltd
Current Assets | 7.2m |
Cash & Short-Term Investments | 5.1m |
Receivables | 2m |
Other Current Assets | 121.6k |
Non-Current Assets | 11.5m |
Intangibles | 11.5m |
Free Cash Flow Analysis
Chimeric Therapeutics Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Chimeric Therapeutics Ltd
Revenue
|
0
AUD
|
Operating Expenses
|
-17.6m
AUD
|
Operating Income
|
-17.6m
AUD
|
Other Expenses
|
-207.1k
AUD
|
Net Income
|
-17.8m
AUD
|
CHM Profitability Score
Profitability Due Diligence
Chimeric Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Score
Chimeric Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
CHM Solvency Score
Solvency Due Diligence
Chimeric Therapeutics Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Score
Chimeric Therapeutics Ltd's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CHM Price Targets Summary
Chimeric Therapeutics Ltd
Dividends
Current shareholder yield for CHM is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CHM
stock under the Base Case scenario is
0.01
AUD.
Compared to the current market price of 0.005 AUD,
Chimeric Therapeutics Ltd
is
Undervalued by 51%.